Kingfisher Biotech: Rabbit

Showing posts with label Rabbit. Show all posts

Monday, October 31, 2016

Rabbit C3a ELISA - Audio Newsletter

Monday, October 3, 2016

Rabbit C3a Do-It-Yourself ELISA, ≤10 Plates

The Rabbit C3a (Complement Component 3a) Do-It-Yourself ELISA (Cat# DIY1220U-003) contains capture antibody, protein standard, and detection antibody for development of a Rabbit C3a ELISA. The antibodies have been determined to function in an ELISA with the standard provided.

C3a is an effector molecule of both the classical and alternative complement pathways for a broad range of functions including T cell activation and survival, angiogenesis stimulation, chemotaxis, mast cell degranulation, and macrophage activation. C3a produces both pro- and anti-inflammatory responses. C3a, a 77 amino acid long anaphylatoxin, is produced when C3 convertases act on the N-terminal chain of the C3 protein. The activation of the C3 protein fragments it into two proteins. The smaller protein, C3a, promotes an inflammatory reaction while the larger, called C3b, binds to the surface of many microbial cells. The binding of C3a to the specific G protein-coupled receptor, C3aR, has been shown to be involved in several diseases such as rheumatoid arthritis, septic shock syndrome, age-related macular degeneration, and asthma. The immune response, initiated by C3a, acts by stimulating mast cell degranulation. Inhibiting the binding of C3a to C3aR with antagonists, such as diiminoisoindolines, diminishes the inflammatory response by disrupting the cascade. In many cases, it has been shown to be strong enough to counteract the pro-inflammatory effects of C5a.

You can find more products for animal health and animal model research at the Kingfisher Biotech website.

Friday, February 19, 2016

VEGF-A Across Species

Kingfisher Biotech's portfolio of VEGF-A recombinant proteins includes, bovine, canine, equine, feline, mouse, ovine, rabbit , rat, swine, and zebrafish VEGF-A.

Vascular endothelial growth factor (VEGF) proteins stimulate vasculogenesis and angiogenesis. They are part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. The normal function of VEGF proteins is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. The VEGF family has six members, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and Placental Growth Factor (PGF). Activity of VEGF-A, as its name implies, has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). In vitro, VEGF-A has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF).

A recent bioassay of our bovine, canine, and mouse VEGF-A based on the proliferation of HUVECs demonstrated that all three proteins are highly active on the human cell line.

Thursday, February 4, 2016

Our Newest Do-It-Yourself ELISAs

Kingfisher Biotech's portfolio of Do-It-Yourself ELISAs continues to grow with the recent addition of Bovine IL-1 beta, Caprine IL-1 beta, Chicken IL-6, and Chicken IL-10 Do-It-Yourself ELISAs. Follow the links below to view product specifications and representative data.

The complete list of Do-It-Yourself ELISAs

Wednesday, January 27, 2016

Rabbit CCL21 (6Ckine) Do-It-Yourself ELISA

Chemokine ligand 21 (CCL21) is a small cytokine belonging to the CC chemokine family. It is also known as 6Ckine (because it has six conserved cysteine residues instead of the four cysteines typical to chemokines), exodus-2, and secondary lymphoid-tissue chemokine (SLC). There are at least 27 distinct members of the C-C subgroup reported for mammals. They are characterized by two adjacent cysteines. CC chemokines induce the migration of monocytes and other cell types such as NK cells and dendritic cells. CCL21 is known to elicit its effects through CCR7.

The Rabbit CCL21 (6Ckine) Do-It-Yourself ELISA (Cat# DIY1121U-003) is the first kit available for the measurement of rabbit CCL21. It contains capture antibody, protein standard, and detection antibody for development of a Rabbit CCL21 (6Ckine) ELISA. The antibodies have been determined to function in an ELISA with the standard provided. Components may also be purchased separately.

Wednesday, July 8, 2015

New Products - July 2015

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We have just started adding cynomolgus monkey and zebrafish products. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Below is a list of our newest recombinant proteins with links to website with additional information on each product.

Thursday, July 2, 2015

Bovine Leukemia Inhibitory Factor (LIF) Polyclonal Antibody Testing

Using our bovine LIF recombinant protein as the antigen, polyclonal antibodies were produced in chickens and screened for recognition of both the glycosylated and deglycosylated forms of bovine, canine, rabbit and swine LIF recombinant proteins. (Previously it was demonstrated that the Kingfisher Biotech LIF recombinant proteins were glycosylated.) The Kingfisher Biotech LIF recombinant proteins were either treated with deglycosylation enzymes or left untreated and were subsequently screened using a Western Blot. The Western Blot showed that the anti-bovine LIF polyclonal antibody recognized both the glycosylated and the deglycosylated forms of bovine (lanes 2 & 3), canine (lanes 4 & 5), rabbit (lanes 6 & 7), and swine (lanes 7 & 8) LIF recombinant proteins.

Thursday, June 4, 2015

Glycosylation of Bovine, Canine, Rabbit, and Swine Leukemia Inhibitory Factor

Kingfisher Biotech expresses recombinant proteins in yeast so they are potentially post-translationally modified. Bovine, canine, rabbit and swine Leukemia Inhibitory Factor (LIF) have calculated molecular weights of 19.8, 19.7, 19.7, and 19.7 kDa, respectively. The Kingfisher Biotech LIF recombinant proteins were treated with deglycosylation enzymes using NEB kit Protein Deglycosylation Mix (NEB Catalog No. P6039S) to determine if the protein produced in yeast is glycosylated. The results show that all four LIF recombinant proteins shifts in molecular weight when treated with the deglycosylation enzymes; the smear of higher MW material appears to be reduced to a single band migrating with the 22/28 kDa doublet standards. The bands showing the molecular weight of the deglycosylation enzymes are also visible. This data suggests Kingfisher Biotech's bovine, canine, rabbit and swine LIF recombinant protein produced in yeast are glycosylated.

Lane	Sample	Treatment
1	Stds-PAGEgel Two-Color SDS Protein Ladder
2	Bovine LIF	Untreated
3	Bovine LIF	Denatured/Deglycosylated
4	Canine LIF	Untreated
5	Canine LIF	Denatured/Deglycosylated
6	Stds-PAGEgel Two-Color SDS Protein Ladder
7	Rabbit LIF	Untreated
8	Rabbit LIF	Denatured/Deglycosylated
9	Swine LIF	Untreated
10	Swine LIF	Denatured/Deglycosylated
11	Stds-PAGEgel Two-Color SDS Protein Ladder
12

MW of Standards: 7.6, 12, 22/28 doublet, 33, 48, 71, 96, 142, 195 kDa.
16% Acrylamide SDS-PAGE Gel (Expedeon)

Thursday, May 28, 2015

New Products - May 2015

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We have just started adding cynomolgus monkey and zebrafish products. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Below is a list of our newest recombinant proteins and specialty products with links to website with additional information on each product.

Thursday, May 7, 2015

LIF Homology Across Species

Bovine, Canine Rabbit, and Swine Leukemia Inhibitory Factor Recombinant Proteins are available from Kingfisher Biotech. Leukemia inhibitory factor, or LIF, is a member of the IL-6 family. LIF affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate.

Thursday, April 23, 2015

Rabbit and Canine Leukemia Inhibitory Factor (LIF) Recombinant Proteins

Kingfisher Biotech's Rabbit and Canine Leukemia Inhibitory Factor (LIF) recombinant proteins can be used in cell culture, as an LIF ELISA Standard, and as a Western Blot Control. Leukemia inhibitory factor, or LIF, is a member of the IL-6 family. LIF affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. Leukemia inhibitory factor derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to LIF include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation. p53 regulated LIF has been shown to facilitate implantation in the mouse model and possibly in humans. Removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. LIF is typically added to stem cell culture medium to reduce spontaneous differentiation.

Kingfisher Biotech's LIF recombinant proteins are intended for use in animal model and animal health research. Our portfolio includes bovine, canine, and rabbit Leukemia Inhibitory Factor (LIF) recombinant proteins. We will be adding Swine Leukemia Inhibitory Factor (LIF) recombinant protein soon.

Thursday, April 16, 2015

New Recombinant Proteins - April 2015

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We will continue to add species as our customer request specific reagents for their research. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Below is a list of our newest proteins with links to website with additional information on each protein.

Thursday, April 9, 2015

IFN gamma Recombinant Proteins - Bovine, Canine, Chicken, Dolphin, Equine, Feline, Human, Mouse, Ovine, Rabbit, and Swine

Bovine, Canine, Chicken, Dolphin, Equine, Feline, Human, Mouse, Ovine, Rabbit, and Swine IFN gamma Recombinant Proteins

IFN-gamma, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Aberrant IFN-gamma expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of IFN-gamma in the immune system stems in part from its ability to inhibit viral replication directly, but, most important, derives from its immunostimulatory and immunomodulatory effects. IFN-gamma is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops.

Kingfisher Biotech offers bovine, canine, chicken, dolphin, equine, feline, human, mouse, ovine, rabbit, and swine IFN gamma recombinant proteins. Our proteins are produced in yeast, making them naturally endotoxin-free - perfect for cell culture applications.

IFN gamma Homology Across Species

Monday, November 14, 2011

TNF alpha Homology Across Species

TNF alpha is involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced mainly by activated macrophages.

TNF alpha is able to induce fever, apoptotic cell death, sepsis (through IL-1 & IL-6 production), cachexia, and inflammation, as well as to inhibit tumorigenesis and viral replication. Because of the broad role of TNF alpha, dysregulation has been implicated in a variety of diseases.

Monday, November 7, 2011

Rabbit as an Animal Model for Tuberculosis Research

The three main animal models employed for the study of tuberculosis (TB) pathogenesis in humans are rabbits, guinea pigs, and mice. All three of these species have the advantages of closely approximating clinical observations as they can be infected by inhalation, display both innate and adaptive immune responses, and generally control the infection initially before it finally becomes fatal. Human TB pathogenesis is a very complex process and no one animal model represents all aspects of the disease. However, rabbit models of TB have the further advantages of displaying cavitation and arrested infection. [1,2]

Rabbit is the only experimental model in which pulmonary cavitation occurs. Pulmonary cavities in rabbits and humans contain huge populations of TB bacteria (~108), which have access to the bronchial tree and therefore the external environment. Given that the degree of contagiousness of TB in humans is typically judged by bacillary burden in sputum culture, the study of cavitation in rabbits is critical to our understanding of TB transmission in humans. Further, the immune systems of rabbits are capable of arresting infection such that they display a latent, or paucibacillary, state similar to humans and in some cases are capable of controlling TB infection so effectively that the bacilli appear to have been completely cleared. While reactivation from a latent state is spontaneous in humans, rabbit reactivation requires immunosuppression. These features make rabbit an important model for the study of human latent TB. [1,2]

References
1. Bosze, Z. and Houdebine, L.M. (2006) Application of rabbits in biomedical research: a review. World Rabbit Sci. 14:1-14.
2. Dharmadhikari, A. and Nardell, E.A. (2008) What animal models teach humans about tuberculosis. Am. J. Respir. Cell Mol. Biol. 39:503-508.

Sunday, October 30, 2011

Rabbit as an Animal Model for Osteoarthritis Research

In humans, osteoarthritis (OA) develops either idiopathically and progresses slowly with age or secondarily to trauma and progresses rapidly. OA is associated with changes to all joint tissues including articular cartilage, subchondral bone, synovium, ligaments, and muscles. Clinically, OA-mediated joint damage results in reduced mobility, pain, and fatigue. While several disease modifying OA drugs are in various stages of development, none have yet been approved for human use. Concurrent research in humans as well as experimental animal models will be important for the discovery of new therapeutics. Since no single experimental model provides the complete picture of OA in humans, a variety of animals have served to advance OA research including mouse, rat, guinea pig, rabbit, dog, and horse. [1,2]
A broad range of rabbit OA models have been used extensively and continue to offer specific advantages over other models for OA research. The gross anatomy of the rabbit knee is very similar to that of humans. Moreover, the rabbit knee joint is large enough to enable the harvest of adequate volumes of tissue for histopathological analysis, a major limitation of smaller animal models. In adult humans, the growth plates in the long bones no longer retain the capacity for growth and are termed “closed.” This is also the case in skeletally-mature rabbits. By contrast, mouse and rat growth plates do not normally close completely and longitudinal bone growth can be reinitiated even in mature animals. This is a complicating issue for data interpretation and limits the translatability of research performed using mice and rats. [2]
Most often, skeletally-mature, male, NZW rabbits are used for OA studies in an attempt to ensure bone growth plate closure, reduce hormone fluctuation, and control for potential inter-strain variability. OA does not occur spontaneously in rabbits, but can be induced via surgical intervention (i.e., meniscectomy or anterior cruciate ligament transection [ACLT]), mechanical manipulation (i.e., impact or immobilization), or chemical application (i.e., IL-1β, collagenase, etc.). The majority of rabbit OA studies employ the ACLT model as it offers several advantages. ACLT-modified rabbits very quickly develop a wide variety of cartilage lesions post-surgically, which closely approximate many aspects of human OA. The histopathology of the rabbit ACLT model has been studied extensively and a standardized nomenclature and scoring scheme for evaluating and comparing alterations in joint structures, including changes in cartilage, synovium and bone, have been proposed. Further, a sizeable body of data derived from this model has already been amassed describing OA pathogenesis including imaging studies and effects of various potential pharmacological applications. [2]
References
1. Poole, R. et al. (2010) Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage 18(Suppl. 3):S10-S16.
2. Laverty, S. et al. (2010) The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthritis Cartilage 18(Suppl. 3):S53-S65.

Sunday, October 23, 2011

Rabbit as an Animal Model for Eye Research

The main advantages to using rabbits as experimental models in eye research are the large size of the rabbit eye relative to its body and the several hundred years worth of accumulated data on the anatomy and physiology of the rabbit eye and its similarity to the human eye. Added to that, the fact that rabbits are easy to handle and breed and the most economical of the larger breed models, makes them ideal for ophthalmic research. [1]

The main avenues of eye research using the rabbit as a model are related to surgical interventions including cataract removal, intraocular lens insertion, corneal transplantation, laser refractive procedures, glaucoma shunt implantation, and intra-vitreal drug delivery. Strain selection is an important consideration for these experiments as the strain most commonly available is albino (New Zealand White [NZW]). Other strains are available that more closely approximate human ocular pigmentation (New Zealand/Dutch Belt or Dutch Belt) for experiments were pigmentation is important. Though there are no differences among male and female rabbits studied using these types of procedures, there are significant age-related differences. For example, young rabbits are commonly used because they have a more robust post-operative inflammatory response, which has been described as similar to that clinically observed in small children. [1]

Other areas of active biomedical research using the rabbit eye as a model include retinal detachment and proliferative vitreoretinopathy (PVR), retinoblastoma, and retinitis pigmentosa (RP). PVR is an abnormal wound healing process that takes place commonly after retinal detachment or other ocular trauma, resulting in a highly inflammatory environment within the eye. Treatment of PVR by vitrectomy or non-specific pharmacological prevention of cell proliferation are only marginally successful. Understanding intra-ocular inflammation is critical to developing new therapeutics for PVR and the rabbit PVR model will undoubtedly facilitate that effort. [2] A new model of retinoblastoma, created by injection of cultured human retinoblastoma cells into the sub-retinal space of immunosuppressed rabbits, displays intraocular tumors after one week that are remarkably similar to those observed in humans and that continue to grow for up to eight weeks. This model also has the advantage of developing viable vitreal tumor seeds when the retinal tumor is still only mid-sized. These vitreous seeds only develop very late in mouse models and are thought to be the cause of treatment failures in humans. This model presents the opportunity to test potential novel chemotherapeutics as well as delivery methods. [3] A new model of RP has been developed via creation of transgenic rabbits bearing a point mutation in the rhodopsin gene. The model has been characterized histologically and electrophysiologically and determined to display progressive retinal degeneration as a result of loss of rod function. While other animals currently serve as models for RP, this new rabbit model will offer additional options for testing therapeutic strategies including implantation of devices or prosthetics and local delivery of drugs or gene therapy. [4]

References
1. Gwon, A. (2008) The rabbit in cataract/IOL surgery. In: Tsonis, P.A. (ed.) Animal models in eye research. Elsevier, pp. 184-204.

2. Zahn, G. et al. (2010) Assessment of the integrin α5β1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and rabbit model of retinal detachment. Invest. Ophthalmol. Vis. Sci. 51(2):1028-1035.

3. Kang, S.J. and Grossniklaus, H.E. (2011) Rabbit model of retinoblastoma. J. Biomed. Biotechnol. 2011:394730.

4. Kondo, M. et al. (2009) Generation of a transgenic rabbit model of retinal degeneration. Invest. Ophthalmol. Vis. Sci. 50(3):1371-1377.

Monday, October 17, 2011

Rabbit as an Animal Model of Alzheimer's Disease

As a result of the rarity of spontaneous Alzheimer’s disease (AD) development in non-human species, animal models mimicking various aspects of this disease have only recently been innovated – typically via dietary, pharmacological, or genetic manipulations. Of these new experimental AD models, the rabbit hypercholesterolemia model, originally developed for the study of atherosclerosis (described above), has a variety of advantages that make it one of the leading models for AD research as well. [1]

Physiologically at the cellular and molecular levels, rabbits fed high-cholesterol diets display many of the neuropathologies observed in humans with AD. The brains of these rabbits show increased levels of cholesterol and Amyloid β (Aβ) and decreased levels of acetylcholine, increased Aβ, tau, and ApoE immunoreactivity, Aβ plaques in the extracellular space, a breakdown in the blood-brain barrier, and an increase in microglial and decrease in neuronal cell populations. The phylogenetic proximity of rabbits and humans is reflected in the 97% amino acid sequence conservation observed between the two species’ Aβ proteins and is a major advantage over other models of AD including fruit flies, mice, and rats. Anatomically, rabbits have larger brains relative to the aforementioned species allowing for greater flexibility in testing for cognitive impairment. Cognitively, rabbits with hypercholesterolemia-induced AD display age-dependent deficits in associative learning that closely parallel those observed in humans. As measured by impairment of eyeblink classical conditioning, these deficits are beyond those observed with normal aging, are specific to AD (i.e., not observed in Parkinson’s Disease or Huntington’s disease), and are relieved upon administration of drugs that improve cognition. No other experimental animal model of AD boasts such an extensive body of existing data by which to judge cognitive impairment as the classically-conditioned eye blink response of rabbits. [1]

Reference1. Woodruff-Pak, D.S. (2008) Animal models of Alzheimer’s disease: therapeutic implications. J. Alzheimers Dis. 15(4):507-521.

Thursday, October 13, 2011

Rabbit as an Animal Model for Atherosclerosis

Atherosclerosis naturally occurs only in humans, a few non-human primates, and pigs. Rabbits, being herbivores, do not develop atherosclerosis naturally, but do consistently develop an atherosclerotic condition that very closely resembles clinical observations when manipulated via dietary or genetic interventions. The rabbit hypercholesterolemia model is perhaps the most well-know of the models and is typically produced by feeding intact rabbits a high-cholesterol diet. After only a few weeks on a modified diet, rabbits develop notable vascular lesions. This rabbit model is highly reproducible with minimal variation between animals in a single laboratory and between laboratories. Two spontaneous lipid metabolism mutants have been characterized and also used extensively in atherosclerosis research – the Watanabe heritable hyperlipidemic (WHHL) rabbit (LDL receptor deficient) and the St. Thomas’ Hospital rabbit (VLDL, IDL, and LDL elevated) serve as models for familial hypercholesterolemia and familial combined hyperlipidemia, respectively. Homozygous WHHL rabbits and St. Thomas’ Hospital rabbits predictably develop atherosclerotic lesions on normal diets. Finally, there are at least 19 transgenic rabbit lines now available specifically for the study of cardiovascular disease that express a wide variety of human transgenes many of which code for proteins implicated in atherosclerosis. [1-3]

These rabbit models closely approximate a variety of aspects of human atherosclerosis and are commonly used to study atherogenesis, plaque instability and rupture, and myocardial infarction. Relative to rodent models, rabbits are much more clinically relevant as many aspects of rabbit lipoprotein metabolism are very similar to humans. Perhaps the most notable differences are that rabbit vascular lesions are more fatty and more inflammatory (as measured by numbers of macrophages present) and rabbit circulating cholesterol levels are higher. An additional advantage to rabbits over rodents is that human transgenes expressed in rabbits produce the expected human-like symptoms while the same transgenes expressed in rodents fail to do so. Further, rabbits are capable of tolerating longer experimental protocols that require monitoring and/or sampling over a period of time whereas individual rodents often can only contribute to a single time point in a study. [1-3]

Rabbit is the first and classical model for human atherosclerosis research and will continue contribute pre-clinical, translational evidence for the safety and efficacy of novel therapies. Perhaps the only animal models that have in some cases surpassed the value delivered by rabbits are the swine models. [1-3]

1. Bosze, Z. and Houdebine, L.M. (2006) Application of rabbits in biomedical research: a review. World Rabbit Sci. 14:1-14.

2. Badimon, L. et al. (2008) Models of behavior: cardiovascular. In: Conn, P.M. (ed.) Sourcebook of models for biomedical research. Humana Press, pp. 361-368.

3. Kónya, A. et al. (2008) Animal models for atherosclerosis, restenosis, and endovascular aneurysm repair. In: Conn, P.M. (ed.) Sourcebook of models for biomedical research. Humana Press, pp. 369-384.

Monday, October 10, 2011

Rabbit as an Animal Model of Human Disease

In the context of biomedical research, rabbits are perhaps most often thought of as bioreactors for the production of monoclonal and polyclonal antibodies and more recently recombinant proteins. However, rabbits are increasingly becoming a valuable experimental model in their own right and are in some cases, the translational model of choice. [1]

Rabbit models do not have the litany of advantages afforded by rodent, or for that matter invertebrate, models in terms of their short life spans, short gestation periods, high numbers of progeny, low inter-individual variability, low cost, advanced genomics and proteomics, and broad availability of reagents. However, rabbits do have many advantages and serve to bridge the gap between these small animal models, which are perhaps best suited for discovery phases of research, and larger animal models often required for pre-clinical, translational research. Rabbits are relatively inexpensive to purchase, house, and maintain as compared to larger animal models. They are easy to breed and handle and are a well-established model in terms of being recognized by the scientific and regulatory communities. Rabbits are phylogenetically closer to primates than rodents and further offer a more diverse genetic background than inbred and out-bred rodent strains, which makes the model a better overall approximate to humans. Further, rabbit genomics and proteomics are advancing rapidly and several transgenic lines have been created and characterized and are readily available. With more researchers using rabbits in their experiments, industry is catching up to their needs and offering an expanding range of rabbit-specific products and services to support them. [1]

Perhaps most importantly, there are some human conditions that cannot be adequately modeled by invertebrate or rodent species and in some cases, the special characteristics of rabbit anatomy and physiology make it uniquely suitable for the study of particular human diseases. [1] Some of the fields for which the rabbit often serves as a primary experimental model include atherosclerosis, Alzheimer’s disease, eye research, osteoarthritis, and tuberculosis. Below is a brief description of how rabbits are crucial to furthering research in these selected areas. This review is intended to be neither comprehensive nor definitive, rather an overview of selected biomedical research fields that employ the rabbit model.

References1. Bosze, Z. and Houdebine, L.M. (2006) Application of rabbits in biomedical research: a review. World Rabbit Sci. 14:1-14.